Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ESA label changes

ESA label changes

Label changes
Renal failure
Added in boxed warning: "Patients experienced greater risks for death and serious cardiovascular events when administered erythropoiesis-stimulating agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3

Read the full 364 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE